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Abstract
Background: Bone morphogenetic proteins (BMPs) have been reported to maintain epithelial integrity and to
antagonize the transforming growth factor β (TGFβ)-induced epithelial to mesenchymal transition. The expression
of soluble BMP antagonists is dysregulated in cancers and interrupts proper BMP signaling in breast cancer.
Methods: In this study, we mined the prognostic role of BMP antagonists GREMLIN 1 (GREM1) in primary breast
cancer tissues using in-house and publicly available datasets. We determined which cells express GREM1 RNA using
in situ hybridization (ISH) on a breast cancer tissue microarray. The effects of Grem1 on the properties of breast
cancer cells were assessed by measuring the mesenchymal/stem cell marker expression and functional cell-based
assays for stemness and invasion. The role of Grem1 in breast cancer-associated fibroblast (CAF) activation was
measured by analyzing the expression of fibroblast markers, phalloidin staining, and collagen contraction assays.
The role of Grem1 in CAF-induced breast cancer cell intravasation and extravasation was studied by utilizing
xenograft zebrafish breast cancer (co-) injection models.
Results: Expression analysis of clinical breast cancer datasets revealed that high expression of GREM1 in breast
cancer stroma is correlated with a poor prognosis regardless of the molecular subtype. The large majority of human
breast cancer cell lines did not express GREM1 in vitro, but breast CAFs did express GREM1 both in vitro and in vivo.
Transforming growth factor β (TGFβ) secreted by breast cancer cells, and also inflammatory cytokines, stimulated
GREM1 expression in CAFs. Grem1 abrogated bone morphogenetic protein (BMP)/SMAD signaling in breast cancer
cells and promoted their mesenchymal phenotype, stemness, and invasion. Moreover, Grem1 production by CAFs
strongly promoted the fibrogenic activation of CAFs and promoted breast cancer cell intravasation and
extravasation in co-injection xenograft zebrafish models.
Conclusions: Our results demonstrated that Grem1 is a pivotal factor in the reciprocal interplay between breast
cancer cells and CAFs, which promotes cancer cell invasion. Targeting Grem1 could be beneficial in the treatment
of breast cancer patients with high Grem1 expression.
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Background
Although carcinomas, which account for approximately 90%
of human cancers, are derived from the epithelia, the tumor
stroma exerts a powerful influence on cancer behavior, such
as tumor cell growth, invasion, metastasis, and evading
immune responses. The tumor stroma consists of cancer-as-
sociated fibroblasts (CAFs); vascular, inflammatory, and im-
mune cells; and extracellular matrix (ECM) residing within
or in the vicinity of a tumor [1]. CAFs are differentiated
from quiescent fibroblasts and are associated with increased
expression of myofibroblastic markers, such as vimentin, α-
smooth muscle actin (αSMA), fibroblast activation protein
(FAP), and fibroblast-specific protein 1 (FSP1, also known as
S100A4) [2]. Tumors, including those from the breast, often
display desmoplasia (a fibrillar network) that is mainly
caused by CAFs, in that they produce and remodel ECM
components, including collagen, fibronectin, and laminin
[3]. The increased stiffness and abnormal physical structure
of the ECM can promote tumor cell growth and metastatic
dissemination and are also critical for the generation and
maintenance of the CAF phenotype [3].
Bone morphogenetic proteins (BMPs) are secreted
growth factors that belong to the transforming growth
factor β (TGFβ) family [4]. Signaling by BMPs is initi-
ated by binding their cognate transmembrane serine/
threonine kinase receptors, which triggers the phosphor-
ylation of intracellular SMAD1/5/8 (R-SMADs). Acti-
vated R-SMADs can form heteromeric complexes with
SMAD4 that accumulate in the nucleus, where they can
regulate transcriptional responses in concert with other
DNA-binding transcription factors [4]. BMP signaling
can elicit diverse and complex biological processes in de-
velopment and disease, including cancer [5]. Many se-
creted BMP antagonists, which sequester BMP ligands
and prevent their binding to receptors, have been identi-
fied [6]. Accumulating evidence indicates that several
cancer types show dysregulated BMP signaling caused
by a disequilibrium of BMPs and their antagonists. For
example, BMP antagonists such as Noggin, Follistatin,
and Chordin like (Chrdl)1 have been linked to induce
osteoclast differentiation and promote osteolytic bone
metastases [7, 8]. The BMP antagonist Coco permits a
few dormant breast cancer cells to escape the quiescent
state imposed by BMP signaling and thereby establish
metastases [9].
Gremlin (Grem) 1 is a highly conserved glycoprotein be-
longing to the Cerberus and Dan subfamily of secreted
BMP antagonists [10]. It preferentially interacts with
BMP2, 4, and 7 [11]. Grem1 is the major BMP antagonist
that maintains proper outgrowth and patterning during
vertebral limb development [12]. Grem1 expression is also
essential for cellular proliferation and branching morpho-
genesis in lung development and in kidney organogenesis
[12, 13]. Aberrant expression in adults is associated with
orofacial clefting [14], osteoarthritis [15], spontaneous
bone fractures [16], and liver [17], lung [18], and renal
[19] fibrosis. Grem1-mediated proangiogenic and pro-
inflammatory activity appears to be independent of its
effects on BMP [20, 21].
In several cancers, Grem1 reduces the negative effect of
BMPs on stemness, proliferation, migration, and invasion
of cancer cells [22–24]. In hereditary mixed polyposis syn-
drome, GREM1 is predominantly expressed in the epithe-
lium of the large bowel, where it disrupts homeostatic
intestinal morphogen gradients and initiates colonic
tumorigenesis [25, 26]. GREM1 was also detected at the
colorectal cancer desmoplastic invasion front, highlighting
a potential role in cancer metastasis [27]. High levels of
GREM1 gene expression were observed in the stromal fi-
broblasts of many types of cancer [23, 28, 29], suggesting
that CAFs are a potential source of Grem1. However, the
effects of Grem1 on CAFs’ function and on the interaction
between (breast) cancer cells and fibroblasts are unclear.
The results presented here support the idea that Grem1
is a clinical predictor of a poor prognosis in breast cancer.
Mechanistically, Grem1 produced by CAFs promoted
fibroblast activation in an autocrine manner and stimu-
lated breast cancer cell stemness and invasion in a para-
crine manner. Grem1 could be an attractive therapeutic
target to interfere with breast cancer progression.
Methods
Data mining of gene expression in clinical patient
samples and 52 breast cancer cell lines
In-house and publicly available gene expression datasets
GSE2034 [30], GSE5327 [31], GSE2990 [32], GSE7390 [33],
and GSE11121 [34] were used for GREM1 (and transform-
ing growth factor β1/2/3 (TGFB1/2/3), interleukin 1β
(IL1B), and tumor necrosis factor α (TNFA)) expression in
lymph node-negative, non-(neo-)adjuvant-treated primary
breast cancer patients with available metastasis-free survival
data, leading to a cohort of 867 patients. Using the
GSE41313 dataset [35], GREM1, BMP, and BMP receptor
expression was assessed in silico in 52 breast cancer cell
lines. Breast cancer dataset GSE14548 [28] was investigated
to explore the GREM1 expression in breast epithelium and
stroma; this dataset was obtained using tissues from normal
breast; grade I, II, and III ductal carcinoma in situ (DCIS),
and invasive breast cancer tissues that were micro-dissected
using a laser capture technique. In addition, the colorectal
cancer dataset GSE39396 [36] was analyzed for GREM1
expression; epithelial cells, leukocytes, fibroblasts, and
endothelial cells were isolated by flow cytometry. Data
were gathered from Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/). Raw.cel files were processed
using frozen robust multiarray analysis (fRMA) parame-
ters (median polish) [37], after which the batch effects
were corrected using ComBat [38].
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GREM1 RNA in situ hybridization (ISH)
A matched breast cancer, adjacent (adenosis or hyperplasia,
and cancer free) and adjacent normal tissue microarray
(TMA) was purchased from US Biomax (BR724). GREM1
RNA in situ hybridization was conducted with an RNA-
scope GREM1 Probe (312831-C2, Advanced Cell
Diagnostics) and a 2.5 HD Detection Kit – BROWN
(322300, Advanced Cell Diagnostics). All procedures
were performed by strictly following the manufacturer’s
instructions. The ISH results were scanned by a digital slide
scanner (Pannoramic 250 Flash III, 3DHISTECH). The pres-
ence of intracellular brown punctate dots was considered as
positive staining. The signal intensity was scored utilizing a
5-point system: 0, no signals visible; 1, weak signals barely
visible; 2, visible signals but not intensive; 3, moderate inten-
sive signals; and 4, intensive signals. Scoring was evaluated
independently by two observers with similar outcomes.
Cell culture
The human breast cancer cell lines MDA-MB-231 and
MCF7 were purchased from ATCC. The human human
telomerase reverse transcriptase (hTERT)-immortalized
breast CAFs 19TT cells have been previously described
[39]. Human foreskin fibroblasts were obtained from Arti
A. Ramkisoensing and have been previously published [40].
These cell lines and human embryonic kidney (HEK)293T
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, 11965092, Thermo Fisher Scientific) supple-
mented with 10% fetal bovine serum (FBS, 16000044,
Thermo Fisher Scientific) and 100U/ml penicillin/strepto-
mycin (Pen/Strep, 15140148, Thermo Fisher Scientific).
MCF10A (M1) human breast epithelial cell line and
MCF10A-derived cell line MCF10A-Ras (M2) were gener-
ously provided by Dr. Fred Miller (Barbara Ann Karmanos
Cancer Institute, Detroit, USA); both cell lines were cul-
tured in DMEM/F12 medium (11039047, Thermo Fisher
Scientific) supplemented with 5% horse serum (26050088,
Thermo Fisher Scientific), 20 ng/ml epidermal growth
factor (EGF, 01-107, Merck Millipore), 10mg/ml insulin
(91077C, Sigma-Aldrich), 100 ng/ml cholera enterotoxin
(C8052, Sigma-Aldrich), 0.5mg/ml hydrocortisone (H0135,
Sigma-Aldrich), and 100U/ml Pen/Strep. Human mesen-
chymal (HM), W18, and W21 fetal mesenchymal stem cells
(MSCs) were isolated and previously described [40] and
cultured in Minimum Essential Medium (MEM) α
(32561037, Thermo Fisher Scientific) with 10% FBS,
100 U/ml Pen/Strep. All cell lines were maintained at 37 °C,
5% CO2, humidified incubator. All fibroblasts and MSCs
were routinely cultured in 0.2% gelatin-coated (G9136,
Sigma-Aldrich) flasks or plates during the whole experiment
period to avoid possible activation caused by physical
rigidity. All cell lines were monthly tested to verify the
absence of mycoplasma, and human cell lines were authen-
ticated by single nucleotide polymorphism (SNP) analysis.
Plasmids, lentiviral transduction, and generation of stable
cell lines
The human GREM1 complementary DNA (cDNA) was
cloned from cDNA by PCR and inserted into the pCDH
lentiviral vector. pLV-mCherry has been described by our
laboratory before [41]. pUltra-Smurf (blue fluorescent
protein AmCyan) was obtained from Addgene (48974,
Addgene). Human GREM1 lentiviral shRNAs were ob-
tained from the Sigma MISSION shRNA library. Five
shRNAs were tested, and the two most effective shRNAs
TRCN0000063833 (sh#1) and TRCN0000063837 (sh#2)
were used.
Lentiviruses were produced by co-transfecting cDNA
expression plasmids or shRNAs with helper plasmids
pCMV-VSVG, pMDLg-RRE (gag/pol), and pRSV-REV
into HEK293T cells using polyethyleneimine (PEI). Cell
supernatants were harvested 48 h after transfection and
stored at − 80 °C. MDA-MB-231 and MCF7 cells were
labeled with mCherry by infecting for 24 h with mCherry-
expressing lentiviral supernatants diluted 1:1 with normal
culture medium in the presence of 5 ng/ml of polybrene
(107689, Sigma-Aldrich). Forty-eight hours after infection,
cells were placed under neomycin (A1720, Sigma-Aldrich)
selection. 19TT and W21 cells were labeled with AmCyan
and subjected to positive fluorescence-activated cell sort-
ing (FACs). To obtain GREM1 stable expressing cell lines,
M1, M2, MDA-MB-231, and W21 cells were infected and
selected with puromycin (P9620, Sigma-Aldrich). Puro-
mycin was used at 1 μg/ml to maintain selection pressure.
After infection with GREM1 targeting shRNAs, 19TT cells
were used within short term as 19TT cells are puromycin
resistant already.
Stimulation with conditioned medium (CM) or cytokines
MDA-MB-231 and MCF7 cells were grown to 70–80%
confluency, washed two times with PBS, and incubated
in serum-free DMEM for 24 h. Conditioned medium
(CM) was then collected and passed through a 0.45-mm
syringe filter (SLHP033RB, Merck Millipore).
19TT cells were treated with CM, recombinant human
TGFβ3 (5 ng/ml, 8420-B3, R&D SYSTEMS and Andrew P.
Hinck, University of Pittsburg, USA), interleukin 1β (IL1β,
10 ng/ml, 201-LB, R&D SYSTEMS), or tumor necrosis fac-
tor α (TNFα, 10 ng/ml, 210-TA, R&D SYSTEMS) for 1, 3, 6,
12, and 24 h. Buffer-treated controls were used in parallel.
For antibody neutralization assays, TGFβ3 or CM was incu-
bated with control (13C4) or TGFβ-neutralizing (1D11)
antibody (generously provided by Sanofi Genzyme, Inc.) for
30min (min) before treatment.
For inhibition of BMP signaling by recombinant hu-
man Grem1 (rhGrem1, 5190-GR, R&D SYSTEMS),
rhGrem1 was pre-incubated with recombinant human
BMP2/6 (5 ng/ml, 355-BM/507-BP, R&D SYSTEMS)
for 30 min.
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Quantitative real-time PCR (qRT-PCR)
Total RNAs were isolated using the NucleoSpin
RNA II kit (740955, BIOKE´). A total of 1 μg of
RNA was reverse transcribed using the RevertAid
First Strand cDNA Synthesis Kit (K1621, Thermo
Fisher Scientific). Real-time PCR was conducted with
GoTaq qPCR Master Mix (A6001, Promega) using
CFX Connect Detection System (1855201, Bio-Rad).
All target gene expression levels were normalized to
GAPDH. The sequences of primers used to detect
target human genes in qRT-PCR were listed in
Additional file 1 Table S1.
CAGA-luciferase reporter assay
HEK293T cells were seeded on a 24-well plate at ap-
proximately 5 × 104 cells per well. The next day, cells
in each well were co-transfected with 0.1 μg TGFβ/
SMAD-inducible (CAGA)12 luciferase transcriptional
reporter construct [42] and 0.08 μg β-galactosidase
expression construct using PEI. After overnight incu-
bation, cells were starved with serum-free medium.
Eight hours later, serum-free media were removed and
replaced by CM from breast cancer cell lines. One
nanogram per milliliter TGFβ3 treatment was per-
formed as a standard. After another overnight incuba-
tion, luciferase and β-galactosidase activities were
measured. The luciferase activity was normalized
based on the β-galactosidase activity.
Western blotting
Cells were lysed with RIPA buffer containing 1 ×
complete protease inhibitor cocktail (11836153001,
Roche). Protein concentrations were determined using
a bicinchoninic acid protein assay kit (5000111, Bio-
Rad). Proteins were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto 45-μm polyvinylidene difluoride
(PVDF) membrane (IPVH00010, Merck Millipore).
Membranes were blocked using 5% non-fat dry milk
in Tris-buffered saline with 0.1% Tween 20 (655204,
Merck Millipore) and probed with the respective primary
and secondary antibodies. The signal was detected using
Clarity™ Western ECL Substrate (1705060, Bio-Rad)
and ChemiDoc Imaging System (17001402, Bio-Rad).
The antibodies used for immunoblotting were raised
against the following proteins: phospho-SMAD1/5/8
(pSMAD1/5/8, home-made) [43], αSMA (A2547,
Sigma-Aldrich), fibronectin (F7387, Sigma-Aldrich),
FAP (WH0002191M1, Sigma-Aldrich), collagen I (ab34710,
Abcam), vimentin (5741, Cell signaling), and glyceraldehyde
3-phosphate dehydrogenase (GAPDH, MAB374, Merck
Millipore). GAPDH was used as a protein loading control.
Flow cytometry
Adherent cells were trypsinized and washed twice with
1% bovine serum albumin (BSA) (A2058, Sigma-Aldrich)
in phosphate-buffered saline (PBS). The cells were then in-
cubated with fluorescein isothiocyanate (FITC)-conjugated
anti-human CD44 (347943, BD Biosciences) and R-phyco-
erythrin (PE)-conjugated anti-human CD24 (555428, BD
Biosciences) antibodies (1:400 dilution) for 30min at 37 °C
in the dark. Fluorescein isothiocyanate (FITC)/PE-conju-
gated IgG isotypes (560952/560951, BD Biosciences)
were used as a control. Cells were washed twice with
1% BSA in PBS and resuspended in 500 ml of PBS
prior to analysis on a FACS Canto flow cytometer
(BD Biosciences).
Phalloidin staining
Cells were fixed in 4% formalin, permeabilized with 0.1%
Triton X-100, and blocked with 5% BSA (A2058, Sigma-
Aldrich) in PBS for 30 min. Then cells were stained with
Alexa Fluor 488 Phalloidin (A12379, Thermo Fisher
Scientific) to visualize filamentous (F)-actin. The nuclei
were stained with 4′,6-diamidino-2-fenylindool (DAPI,
62248, Thermo Fisher Scientific). Images were taken by
confocal microscopy (SP8, Leica Microsystems).
Mammosphere formation assays
Single-cell suspensions of M1 cells were prepared in
DMEM/F12 medium containing 1× B27 (17504044,
Thermo Fisher Scientific), 20 ng/ml epidermal growth
factor (01-107, Merck Millipore), 20 ng/ml fibroblast
growth factors (PHG6015, Thermo Fisher Scientific),
and 4mg/ml heparin (H3149, Sigma-Aldrich). Then,
2000 cells/well were seeded into ultralow attachment
24-well plate (CLS3473-24EA, Corning). After 10 days of
standard incubation, the numbers of spheres (> 75mm
diameter) were counted using an inverted microscope
(DMi8, Leica Microsystems). For secondary sphere for-
mation, primary spheres were dissociated with Accutase
(A1110501, Thermo Fisher Scientific), followed by 25-
gauge needles (Z192406, BD Biosciences) mechanically.
Next, 2000 cells/well were replated. Sphere-forming effi-
ciency was calculated as the number of spheres (average
diameter = 100 μm) formed divided by the number of
single cells originally seeded.
Collagen gel contraction assays
The contraction assay [44] was performed to evaluate
the contractility of 19TT cells with GREM1 knockdown
or GREM1-overexpressing W21 cells. Collagen gels were
prepared by mixing fibroblast cell suspensions in serum-
free medium and type I collagen (Corning, 354249) solu-
tion. The final cell density was 2.0 × 105 cells/ml with 1
mg/ml collagen. A 0.5-ml mixture was casted into each
well of a 24-well plate and allowed to polymerize for 30
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min at 37 °C. Following gelatinization, another 0.5 ml of
serum-free DMEM was added to the gel. Changes of gels
were recorded by using a ChemiDoc Imaging System
(17001402, Bio-Rad) at a fixed distance above the gels at
24, 48, and 72 h. The surface area of the gels was quanti-
fied by ImageJ software. The percentage of contraction
was calculated using the formula 100% × (well surface
area − gel surface area)/well surface area.
Three-dimensional spheroid invasion assay
mCherry-labeled MDA-MB-231 or MCF7 cells and co-
culture (1:1 mixture) with W21 or 19TT groups were
prepared at 1000 cells/ml in complete DMEM. Drops of
the single-cell suspension (30 μl) were placed onto the
lids of 10-cm dishes, which were inverted over dishes
containing 10ml PBS. Hanging drop cultures were incu-
bated 7 days allowing sufficient sedimentation and for-
mation of one spheroid per drop. Images were taken by
an inverted fluorescent microscope (DMi8, Leica
Microsystems).
The 3D spheroid invasion assay was performed accord-
ing to our previous study [45] with slight modifications.
Single spheroids were embedded in the center of each well
of a flat-bottom 96-well plate pre-coated with 50 μl of
collagen mixture. Type I collagen (354249, Corning) was
neutralized according to the manufacturer’s protocol. The
collagen mixture was prepared by diluting neutralized col-
lagen with serum-free medium to a final concentration of
2mg/ml. Eight spheroids generated by each experimental
setting were randomly chosen for embedding. After spher-
oid embedding, another 50 μl of collagen mixture was
overlaid onto the collagen matrix in each well. The plate
was incubated for 30min at 37 °C to solidify the gels.
Thereafter, 50 μl of serum-free medium was added to each
well to prevent the surface from dehydrating. Plates were
placed under standard cell culture conditions. Images
were taken at days 0, 2, and 4 after embedding by using
inverted fluorescence microscopy (DMi8, Leica Microsys-
tems). The invasion was quantified by measuring the area
occupied by cells using ImageJ software.
Embryonic zebrafish intravasation and extravasation
assay
Zebrafish xenograft breast cancer cell experiments were
performed by injecting fluorescently labeled breast cancer
cells into embryos at 48 h post-fertilization as described be-
fore [41]. Briefly, approximately 400 mCherry-labeled
MDA-MB-231 cells were injected into the perivitelline
space or the duct of Curvier (DoC) of transgenic zebrafish
embryos (fli: enhanced green fluorescent protein (EGFP)),
whose vasculature is marked in green. For co-injection,
mCherry-labeled MDA-MB-231 cells and AmCyan-labeled
W21 or 19TT cells were mixed at a ratio of 1:1. Then,
approximately 400 mixed cells were injected into the
zebrafish perivitelline space. Zebrafish embryos were main-
tained at 34 °C after injection, a compromise for both the
fish and the human cell lines. Three days post-injection
(dpi) into the perivitelline space, the MDA-MB-231 cells
that intravasated from the cell mass toward the embryonic
fish body within the head and tail regions were imaged and
counted under a confocal microscope (SP5 STED, Leica
Microsystems). At 5 dpi into the DoC, the number of
MDA-MB-231 cells that extravasated individually from the
circulation into the collagen fibers of the tail fin or the
number of clusters formed by M2 cells collectively was
analyzed. At least 200 zebrafish embryos were injected for
each condition. After verification by microscopy, only
correctly injected and viable zebrafish were used for
experimental analysis. All experiments were repeated
at least two times independently, and representative
experiments are shown.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 7.0. Numerical data from triplicates are presented
as the mean ± standard deviation (s.d.), except for the ana-
lysis of zebrafish experiments, where a representative re-
sult is expressed as the mean ± standard error (s.e.m).
Experiments were analyzed with an unpaired Student’s t
test. P < 0.05 was considered statistically significant.
Results
High GREM1 expression in breast tumors is associated
with a poor prognosis
BMPs have been reported to maintain epithelial integrity
and to antagonize TGFβ-induced epithelial to mesenchy-
mal transition (EMT), an important process for cancer
cell invasion and metastasis [5]. Many soluble BMP an-
tagonists have been described to be misexpressed and to
interrupt proper BMP signaling in breast cancer [7–9].
We examined the prognostic role of soluble BMP antag-
onists in primary breast cancer using an in-house and
publicly available cohort of 867 untreated lymph node-
negative breast cancer patients (see the “Methods” sec-
tion for datasets that were used). The median follow-up
time of metastasis-free survival (MFS) was 94.1months
(range from 1 to 299.4months). High expression of
GREM1 was found to be associated with a poor prognosis
among all BMP antagonists that were examined. As
shown in Fig. 1a, according to the GREM1 mRNA expres-
sion level, the subjects were divided evenly into three
quantiles: low, middle, and high. GREM1 expression was
inversely associated with MFS in this cohort, i.e., higher
expression, and poorer outcome (low vs high: HR (hazard
ratio) = 1.35, 95% confidence interval (CI) 1.15–1.57, log
rank P = 0.00018; low vs middle: HR = 1.41, CI 1.02–1.96,
P = 0.036; middle vs high: HR = 1.31, CI 0.98–1.74, P =
0.065). A similar association was observed when dividing
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Fig. 1 Stromal expression of GREM1 predicts poor clinical outcome in breast cancer. a Kaplan-Meier survival curve in untreated lymph node-
negative breast cancer patients. Based on GREM1 mRNA expression (low, middle, and high), the subjects (N = 867) were divided into three
quantiles. The endpoint is distant metastasis-free survival. b GREM1, BMP, and BMP receptor mRNA expression level in 52 breast cancer cell lines.
The expression levels were categorized to four groups: background, low, intermediated, and high. c Human GREM1 in situ hybridization shows
restricted GREM1 expression in fibroblast-like stromal cells surrounded by malignant breast epithelial cells. d Scatterplot showing positive
correlation between the expression of GREM1 and stromal genes/desmoplastic markers FAP, FN1, FBN1, and COL1A1 in the clinical datasets.
Pearson’s coefficient tests were performed to assess the statistical significance
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subjects into two quantiles (Additional file 2: Figure S1a).
Furthermore, high expression of GREM1 correlated
with a poor prognosis in all the breast cancer molecu-
lar subtypes examined: human EGF receptor (HER)2+,
triple−, estrogen receptor (ER)+, and ER− (Additional file 2:
Figure S1b-e). Therefore, GREM1 is a poor prognostic
marker of metastasis-free survival in breast cancer regard-
less of the subtype.
GREM1 is expressed in cancer-associated fibroblasts
When we examined the GREM1 expression in 52 human
breast cancer cell lines by mining previously published
datasets (see the “Methods” section), we found that only
3 breast cancer cell lines express low (MDA-MB-436
and HCC38) or intermediate (SUM149PT) levels of
GREM1; all other 49 cell lines had no detectable expression
(Fig. 1b). To explore the source of GREM1 expression, we
stained GREM1 RNA by using in situ hybridization (ISH)
in a breast cancer TMA, which comprised 24 matched
cases of invasive ductal carcinoma, adjacent tissue, and
adjacent normal tissue. As shown in Table 1 and Fig. 1c,
we identified variable amounts of GREM1 expressed in
fibroblast-like cells, i.e., CAFs, whereas there were no de-
tectable levels of GREM1 in cancer-adjacent normal tissues
or adjacent cancer-free breast tissues. None of the epithe-
lial cells of breast cancers included in this study showed
GREM1-positive expression. The GREM1 expression in
breast cancer tissue samples is thus mainly caused by
the presence of tumor stroma. Moreover, using the in-
house and publicly available primary breast cancer
datasets, we observed a significant positive correlation
between GREM1 and markers for CAFs and tumor
matrix stiffness/desmoplasia, such as FAP, fibronectin
(FN)1, fibrillin (FBN)1, collagen (COL)1A1, thrombos-
pondin (THBS)2, and a-actin (ACTA)2 (Fig. 1d, Add-
itional file 2: Figure S1f). Taken together, these results
suggest that CAF-derived Grem1 might play a pivotal
role in promoting breast tumor progression.
TGFβ secreted by cancer cells and inflammatory cytokines
induces GREM1 expression
Analysis of GREM1 in tissue sections revealed that only
the CAFs in close proximity to the cancer cells (tumor-
stromal interface) showed high GREM1 RNA expression
(Fig. 1c, bottom panel). We therefore explored the possi-
bility that fibroblasts express GREM1 in response to fac-
tors secreted by cancer or inflammatory cells. We first
collected CM from M1 immortalized normal breast cells
and breast cancer cell lines MCF7 and MDA-MB-231.
Treatment of 19TT CAFs (Fig. 2a) or W21 MSCs (Add-
itional file 3: Figure S2a) with MDA-MB-231 or MCF7 cell
CM resulted in a significant increase in GREM1 mRNA
levels. There was no effect of M1 CM on GREM1 expres-
sion. To explore the factors that are responsible for indu-
cing GREM1 expression in CAFs, we analyzed by data
mining the expression of TGFB1/2/3 and inflammatory
cytokines in breast cancer cell lines as well as in breast
cancer tissues. We found that TGFB1/2/3 are highly
expressed in both breast cancer cell lines and tissues. In-
flammatory cytokines, including IL1B and TNFA, were
expressed in breast cancer tissues but only at very low
levels in breast cancer cell lines (Fig. 2b, c). IL1B and
TNFA expression in breast cancer tissues are thus
likely caused by the stromal cells present in breast can-
cer tissue samples. Challenging 19TT CAFs (Fig. 2d) or
W21 MSCs (Additional file 3: Figure S2b) with TGFβ3,
TNFα, and IL1β promoted GREM1 mRNA expression.
Next, we analyzed whether TGFβ is secreted by cancer
cells. MDA-MB-231 and MCF7, but not M1, were
found to express active TGFβ (Fig. 2e). Importantly,
the GREM1 expression-inducing activity of MDA-MB-231
or MCF7 cells could be blocked by a TGFβ-neutralizing
antibody (Fig. 2f). Taken together, TGFβ secreted by can-
cer cells is the main determinant for inducing GREM1
expression by CAFs. Within the tumor-stroma niche, in-
flammatory cells secreting cytokines may also contribute to
GREM1 expression by CAFs.
Grem1 increases mammosphere formation
BMPs are reported to be inhibitors of cell stemness, suggest-
ing that secreted Grem1 might oppositely affect the stem
traits [9, 22, 46]. First, we confirmed that BMPs and BMP re-
ceptors are indeed expressed in breast cancer cell lines
(Fig. 1b, Additional file 4: Figure S3a and b). Then, mammo-
sphere formation assay was performed to assess the effect of
Grem1 on mammary stem cell activity in vitro. GREM1-
overexpressing M1 cells exhibited twofold more sphere
formation compared to control cells in each of two subse-
quent passages (Fig. 3a). The administration of exogenous
rhGrem1 showed a similar effect on mammosphere forma-
tion of M1 cells, whereas the administration of exogenous
BMP2 mitigated sphere formation ability. The latter could
be reversed by the concurrent administration of rhGrem1
(Fig. 3b). The surface expression of CD44+/high CD24−/low
cells has been considered a stem population marker
of breast cancers or cell lines [46]. Flow cytometry
analysis demonstrated a significant increase in the
Table 1 RNA ISH scores for GREM1 in matched breast cancer
tissue microarray
RNA ISH score Adjacent normal
tissue (%)
Adjacent
tissue (%)
Invasive ductal
carcinoma (%)
0 24 (100) 24 (100) 4 (16.67)
1 0 (0) 0 (0) 6 (25.00)
2 0 (0) 0 (0) 5 (20.83)
3 0 (0) 0 (0) 5 (20.83)
4 0 (0) 0 (0) 4 (16.67)
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CD44+/high CD24−/low cell subpopulation in GREM1-
overexpressing M1 cells compared to the control (Fig. 3c).
qRT-PCR revealed that GREM1 OE (Fig. 3d) or rhGrem1
(Additional file 4: Figure S3c) increased the expression of
transcriptional regulators YAP, TAZ, SOX2, and OCT4,
which have been implicated in maintaining breast cancer
stemness. Moreover, M1 cells treated with rhGrem1 or
the BMP type I receptor inhibitor LDN193189 [47] also
displayed more CD44+/high CD24−/low cells than non-
treated control cells (Fig. 3e). These results suggest that
Grem1 enhances the mammosphere formation of M1 cells
by repressing BMP signaling.
Grem1 promotes breast cancer cell invasion
To further characterize the role of Grem1 in breast can-
cer, we stably expressed Grem1 in the breast cancer cell
lines M2 and MDA-MB-231 with a lentiviral vector. In a
way, these transfected cell lines are somewhat reminis-
cent to the few breast cancer cell lines that express
GREM1. In these GREM1-overexpressing cell lines,
BMP-induced SMAD1/5/8 phosphorylation (Fig. 4a) and
expression of BMP target genes ID1 and 3 (Fig. 4b) were
clearly inhibited. Notably, the mRNA levels of the mes-
enchymal markers SLUG, SNAI1, VIM, and NCAD were
increased by ectopic GREM1 expression (Fig. 4c, d) or ex-
ogenous rhGrem1 treatment (Additional file 5: Figure S4b),
suggesting that Grem1 induces a slightly more mesenchy-
mal phenotype in these breast cancer cells. To test whether
exposure to Grem1 also results in more invasive behavior,
we introduced these cells into the blood circulation of
embryonic zebrafish via DoC injection and examined ex-
travasation 5 days post-injection (dpi) in the avascular tail
fin area. Compared to the vector control, the GREM1 over-
expression group showed a higher number of extravasated
M2 cell clusters (Fig. 4e) or MDA-MB-231 single cells
(Fig. 4f). The BMP/SMAD signaling could be inhibited by
exogenous administration of rhGrem1 (Additional file 5:
Figure S4b). Next, we injected MDA-MB-231 cells sus-
pended in PBS supplemented with or without rhGrem1
into the perivitelline space of embryonic zebrafish and
examined the level of cells in circulation at 3 dpi. Exoge-
neous rhGrem1 increased cellular intravasation signifi-
cantly, as more cells were found in the head and tail
regions of zebrafish embryos (Fig. 4g).
Grem1 promotes fibroblast activation
Grem1 is associated with fibrosis [17–19]. To explore
the role of Grem1 in fibroblast activation, we first
compared GREM1 mRNA expression levels in foreskin
fibroblasts, 19TT breast cancer CAFs, and HM, W18,
and W21 human mesenchymal stem cells (MSCs). M2,
MCF7, and MDA-MB-231 cancer cells served as a nega-
tive control. MSCs, which are considered fibroblast pre-
cursors and can differentiate into fibroblasts [2], showed
the lowest expression of GREM1; GREM1 expression in
the foreskin fibroblasts, which represent normal fibro-
blasts, was significantly higher than that in MSCs, and
19TT CAFs showed the highest levels (Fig. 5a), indicat-
ing that GREM1 expression increases during different
stages of fibroblast activation. We next knocked down
GREM1 in 19TT CAFs. As shown in Fig. 5b, two
shRNAs-mediated GREM1 knockdown increased the
mRNA expression of both ID1 and ID3 and decreased
the expression of TGFβ signaling components and their
target genes (plasminogen activator inhibitor (PAI-1),
fibroblast activation markers, and matrix metalloprotein-
ases (MMPs). GREM1 knockdown in 19TT CAFs also
led to decreased protein levels of FN1, S100A4, collagen
I, FAP, and αSMA (Fig. 5c). This result suggests that
Grem1 is a pivotal factor in fibroblast activation.
To examine whether Grem1 affects the cytoskeletal
changes, we stained the cells with fluorescein-conjugated
phalloidin to visualize filamentous (F)-actin. Indeed,
GREM1 knockdown in 19TT CAFs resulted in less
prominent stress fibers and less organized bundles in the
cytoplasm (Fig. 5d). More significantly, the ability of
19TT CAFs to contract collagen gels (a 3D model widely
used for evaluating fibroblast-mediated matrix remodel-
ing capacity) decreased significantly with GREM1 knock-
down (Fig. 5e). Moreover, GREM1 overexpression in
(See figure on previous page.)
Fig. 2 TGFβ secreted by breast cancer cells and inflammatory cytokines induce GREM1 expression in CAFs. a GREM1 expression in 19TT CAFs after
treatment with conditioned medium (CM) from breast cell lines (M1, MDA-MB-21, or MCF7). The expression was normalized to the parallel time
control of normal medium treatment. The results are expressed as the mean ± s.d, n = 3. Student’s t test, *P < 0.05, ***P ≤ 0.001. b TGFB1, TGFB2,
TGFB3, TNFA, and IL1B mRNA levels in 52 breast cancer cell lines. The expression levels were categorized into four groups: background, low,
intermediated, and high. c TGFB1/2/3, TNFA, and IL1B expression in primary breast cancer samples. The expression level was categorized into four
groups: background, low, intermediated, and high. d TGFβ3 (5 ng/ml), TNFα (10 ng/ml), or IL1β (10 ng/ml) induce GREM1 expression in 19TT
cancer-associated fibroblasts (CAFs). Expression was normalized to the parallel time control of buffer treatment. The results are expressed as the
mean ± s.d., n = 3. Student’s t test, *P < 0.05, **P≤ 0.01, ***P≤ 0.001. e Measurements of TGFβ activity in CM from breast cancer cell lines using a
CAGA luciferase (LUC) reporter assay in HEK293T cells as a readout. TGFβ-neutralizing antibody (10 ng/ml) was added to demonstrate that luciferase
activity in CM is due to the TGFβ activation and not activins or nodal. Recombinant TGFβ was added to control for the functionality of the assay. The
value is normalized to β-galactosidase (βGal) activity. The results are expressed as the mean ± s.d, n = 3. Student’s t test, ***P≤ 0.001. f The induction of
GREM1 expression in 19TT CAFs by CM from MCF7 and MDA-MB-21 is blocked by TGFβ-neutralizing antibody. The results are expressed as the
mean ± s.d, n = 3. Student’s t test, **P≤ 0.01
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Fig. 3 Grem1 maintains stemness in M1 cells. a GREM1 overexpression (OE) induces more mammosphere formation in M1 cells. Left,
representative images of mammospheres at 7 days. Right, the number of spheres formed per 1000 cells plated. The primary spheres were
disintegrated and replated further. Secondary spheres formed were counted. The results are expressed as the mean ± s.d., n = 3. Student’s t test,
**P ≤ 0.01. b Pro-mammosphere formation ability of recombinant human Grem1 (rhGrem1) protein (500 ng/ml) can be neutralized by BMP2 (50
ng/ml). Left, representative images of spheres at 7 days; right, the number of spheres formed per 1000 cells plated. The results are expressed as
the mean ± s.d., n = 3. Student’s t test, **P ≤ 0.01. c Flow cytometry analysis shows that GREM1 OE in M1 cells increases the stem population
(CD44+/high CD24−/low). d GREM1 OE in M1 cells upregulates stem cell transcription factors. GAPDH was used as an internal control. The results are
expressed as the mean ± s.d., n = 3. Student’s t test, *P < 0.05, ***P ≤ 0.001. e Flow cytometry analysis showing that 2 days of treatment with
rhGrem1 (500 ng/ml) or the BMP type I receptor inhibitor LDN193198 (120 nM) also leads to an increase in the CD44+/high CD24−/low population
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Fig. 4 Ectopic expression of GREM1 promotes cancer cell invasion in a zebrafish model. a, b GREM1 overexpression (OE) inhibits BMP-induced
SMAD1/5/8 phosphorylation (pSMAD1/5/8 (a)) and the BMP target genes ID1 and ID3 (b) in MDA-MB-231 and M2 cell lines. GAPDH was used as
an internal control. The results are expressed as the mean ± s.d., n = 3. Student’s t test, **P ≤ 0.01. c, d GREM1 OE upregulates the expression of
EMT transcription factors and markers in M2 (c) and MDA-MB-231 (d) cells. GAPDH was used as an internal control. The results are expressed as the
mean ± s.d., n = 3. Student’s t test, **P≤ 0.01. e, f GREM1 OE induces more clusters formation in M2 cells (e) and promotes the invasion of MDA-MB-
231 cells (f) in zebrafish. Left, quantification of the number of extravasated cells/clusters at 5 days post-injection (dpi). Right, representative images:
green, vasculature of zebrafish; red, mCherry-labeled cells. The results are expressed as the mean ± s.e.m., n = 2. Student’s t test, **P≤ 0.01, ***P≤ 0.001.
g Perivitelline space injection of MDA-MB-231 cells supplemented with rhGrem1 (1 μg/ml) increases cell intravasation in zebrafish. Left, representative
images: green, vasculature of zebrafish; red, mCherry-labeled cells. Right, quantification of the number of intravasated cells in each embryonic body at
3 days post-injection (dpi). The results are expressed as the mean ± s.e.m., n = 2. Student’s t test, *P < 0.05
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W21 MSCs (Additional file 6: Figure S5a) induced inten-
sive myofibroblast-like characteristics (Additional file 5:
Figure S5b-e). Consistent with this result, W21 MSCs
treated with rhGrem1 or the selective BMP receptor kin-
ase inhibitor LDN193189 exhibited an upregulation of
genes which were inhibited by GREM1 knockdown in
19TT CAFs (Additional file 6: Figure S5f). Overall, these
observations imply that Grem1 is closely associated with
the fibrogenic phenotype of breast CAFs.
Fibroblast-derived Grem1 promotes breast cancer cell
invasion in a 3D spheroid model
Previous studies have indicated that CAFs are propel-
lants of cancer cell invasion [1, 2]. Prompted by the pro-
fibrotic role of Grem1, we further explored the roles of
Grem1 in fibroblast-mediated cancer cell invasion using
a 3D spheroid model. As illustrated in Additional file 7:
Figure S6a, spheroids were produced from hanging drop
co-cultures of mCherry-labeled breast cancer cells,
MCF7 or MDA-MB-231 cells, and AmCyan-labeled
19TT CAFs. CAFs with or without GREM1 knockdown
were mixed with these breast cancer cells at a 1:1 ratio.
The various resulting spheroids were embedded in colla-
gen gel. As shown in Additional file 7: Figure S6b, the
monocultured MCF7 spheroid showed a collective cell
invasion phenotype in collagen, and in the presence of
19TT cells, the increased invasion of CAFs was mea-
sured at day 4. However, upon GREM1 depletion in the
19TT CAFs, the co-culture spheroids showed strongly
reduced invasion (Fig. 6a). Likewise, GREM1 knockdown
in the CAFs reduced the invasion of MDA-MB-231 cells
in MDA-MB-231 and 19TT co-culture spheroids at days
2 and 4 (Fig. 6b).
Fibroblast-derived Grem1 promotes breast cancer cell
intravasation
Next, we examined the role of fibroblast-expressed Grem1
in breast cancer cell invasion in vivo. We injected
mCherry-labeled MDA-MB-231 cells into the perivitelline
space of zebrafish in the absence or presence of either
AmCyan-labeled W21 MSCs, foreskin fibroblasts, or 19TT
CAFs. As depicted in Fig. 7a, intravasation of the
MDA-MB-231 cells was significantly increased when
co-implanted with W21, validating a previous study in
which MSCs promoted cancer metastasis [48]. Import-
antly, this intravasation was much more enhanced by the
foreskin fibroblasts and even more so by the 19TT CAFs,
suggesting a correlation with their GREM1 expression
level. Indeed, the ectopic expression of GREM1 in W21
cells resulted in enhanced MDA-MB-231 cell intravasa-
tion upon co-injection (Additional file 8: Figure S7). Con-
sistent with this result, GREM1 knockdown mitigated the
promotion role of 19TT CAFs on MDA-MB-231 cell
intravasation (Fig. 7b).
Discussion
Our work has uncovered a strong association between
high GREM1 expression in breast tumor biopsies and a
poor prognosis. We provide mechanistic insights into
GREM1’s key role in facilitating breast cancer progres-
sion using in vitro and in vivo studies. Grem1 is highly
expressed by CAFs at the invasion front; its expression
can be promoted by factors, such as TGFβ released by
breast cancer cells and inflammatory cytokines. Grem1
mediates the fibrogenic activation of CAFs in an auto-
crine manner. Grem1 has a direct effect on cancer cell
invasion and stemness, evidenced by the fact that it pro-
moted a slightly more mesenchymal/stemness phenotype
in breast cancer cells. It could also contribute indirectly
to this process via its potent effects on fibroblast activa-
tion. In this way, Grem1 promotes the formation of a
microenvironment conducive to breast cancer cell inva-
sion. Thus, Grem1 is a key determinant of the mutual
interplay between breast cancer cells and CAFs (Fig. 7c).
Although we found an association between Grem1
and poor breast cancer prognosis, the prognostic signifi-
cance of Grem1 in different cancer types is not consist-
ent. For example, Grem1 expression correlates with
progression-free survival in pancreatic neuroendocrine
tumors [49] and colorectal cancer [50], but it is an indi-
cator of poor progression-free survival in cervical cancer
[51]. Grem1 may have different roles in different tumor
types, but this may be dependent on the experimental
setup, the analysis of expression in complete tumors vs
stromal expression specifically, and/or the determining
the levels of RNA vs protein. For instance, when testing
(See figure on previous page.)
Fig. 5 GREM1 knockdown in 19TT breast cancer-associated fibroblasts (CAFs) attenuates fibrotic characteristics. a qRT-PCR comparison of relative
GREM1 expression in M2, MCF7, MDA-MB-231, HM, W18, and W21 fetal mesenchymal stem cells (MSCs), foreskin fibroblasts, and 19TT CAFs. GAPDH
was used as an internal control. The results are expressed as the mean ± s.d., n = 3. Student’s t test, **P≤ 0.01, ***P≤ 0.001. b qRT-PCR analysis of the
selected genes, BMP targets, TGFβ pathway constituents/targets, fibroblast activation markers, and matrix metalloproteinases in 19TT CAFs with/
without shRNA-mediated GREM1 knockdown. GAPDH was used as an internal control. The results are expressed as the mean ± s.d., n = 3. Student’s t
test, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. c Western blot analysis to detect the changes in indicated proteins after GREM1 knockdown in 19TT CAFs. d
19TT CAFs with/without GREM1 knockdown were stained with fluorescein-phalloidin (green) to visualize F-actin. DAPI was used for nuclear staining
(blue). e Collagen gel contraction assay. 19TT CAFs with/without GREM1 knockdown were embedded in collagen gels. After 24, 48, and 72 h, the area
of each gel (white dash circle) was imaged and quantified. Left, representative images of contracted gels. Right, the percentage of gel contraction.
Quantification is shown in the “Methods” section. The results are expressed as the mean ± s.d., n = 3. Student’s t test, **P≤ 0.01
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commercial antibodies on tissue sections, including
sections of GREM1-deficient animals, we found that the
detected signals may not have been specific for Grem1
(data not shown). To avoid these putatively non-specific
measurements, we determined GREM1 mRNA levels by
in situ hybridization.
The mRNA detection method revealed that GREM1
was exclusively expressed by CAFs. Our findings are sup-
ported by our data mining of publicly available datasets.
We analyzed breast cancer dataset GSE14548 generated
by Ma and colleagues [28], which separated epithelial and
stromal tissues, and in this dataset, GREM1 was found
mainly expressed in the (invasive) breast cancer stroma,
and there was no GREM1 expression observed in normal
epithelium and stroma (Additional file 9: Figure. S8a). In
addition, we mined a colon cancer dataset GSE39396 in
which epithelial cells, leukocytes, fibroblasts, and endothe-
lial cells were separately isolated by FACs and thereafter
profiled. Consistent with our results, only fibroblasts were
found to express GREM1 (Additional file 9: Figure S8b).
We found that GREM1 expression in CAFs is particu-
larly high in close vicinity of cancer cells. This is consist-
ent with previous reports in which Grem1 was found to
be highly expressed in CAFs in the microenvironment of
basal cell carcinoma (and other tumors) compared to
normal tissue counterparts [23] and a study of colorectal
Fig. 6 GREM1 knockdown in 19TT breast cancer-associated fibroblasts (CAFs) impairs breast cancer cell invasion in a 3D spheroid invasion model.
a, b Collagen invasion assay of co-culture spheroids. Eight spheroids per indicated group were embedded into collagen. Left, representative
images of 3D spheroid invasion at days 0, 2, and 4. Red, MCF7 (a) or MDA-MB-231 (b) cells; blue, 19TT cells with/without GREM1 knockdown.
Right, relative invasion area was quantified as the area difference at days 2 and 4 relative to that at day 0. The results are expressed as the
mean ± s.d., n = 8. Student’s t test, *P < 0.05, **P ≤ 0.01
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cancer, in which Grem1 was found to be expressed at
the invasion fronts in CAFs and to mediate the loss of
cancer cell differentiation [3]. We identified TGFβ
secreted by cancer cells as a strong driver of GREM1
expression by CAFs. Moreover, clinical breast cancer
samples were also found to highly express TGFB1/2/3
suggesting that these findings are of clinical relevance.
Such invasion fronts are rich in inflammatory cells [52].
Consistent with this result, we found that inflammatory
cytokines IL1β and TNFβ induced GREM1 expression in
CAFs. Moreover, GREM1 expression correlated with
mesenchymal marker expression in tumor samples. The
latter observation indicates that Grem1 at the invasion front
may contribute to the desmoplastic phenotype (Fig. 7).
We observed a striking activation of fibrogenesis in
fibroblasts and in CAFs by Grem1. Depletion or ectopic
expression of Grem1 in CAFs demonstrated that Grem1
expression is positively linked to the expression of TGFβ
ligands and target genes, mesenchymal markers, extra-
cellular matrix proteins, and matrix metalloproteinase
(MMP) remodeling factors at the mRNA level, as well as
with fibronectin, S100A4, collagen I, FAP, and αSMA at
the protein level. In addition, Grem1 promoted actin
stress fiber formation and collagen gel contraction.
These expression patterns are a characteristic of a fibro-
genic response and fibroblast activation. The Grem1-in-
duced responses may be mediated by TGFβ pathway
activation; TGFβ is a strong inducer of fibrogenesis and
an activator of fibroblasts [53]. With TGFβ being a
strong inducer of Grem1 and vice versa, it may act in a
feed-forward loop.
Multiple studies have shown that CAFs create a micro-
environment suitable for cancer cell invasion [1, 2],
which we further demonstrated in this study in vivo by
co-injection of breast cancer cells with fibroblasts/CAFs
into the zebrafish perivitelline space. Thus, the profibro-
genic ability of Grem1 could contribute to its role in
promoting cancer cell invasion mediated by activated
fibroblasts and CAFs. 3D co-culture of breast cancer
cells with CAFs in collagen demonstrated that Grem1 is
critical for invasion. In accordance with these results,
Grem1 strongly promoted intravasation in a zebrafish co-
injection xenograft model. Moreover, by injecting ectopic
Grem1-producing M2 and MDA-MB-231 cells into the
DoC of zebrafish embryos, we found that Grem1 strongly
promoted the extravasation of cancer cells. These results
may explain the clinical association between Grem1 ex-
pression in tumors and a poor prognosis of MFS.
Mechanistically, Grem1 exerts its effects by antagoniz-
ing selective BMPs [11]. Consistent with this notion, we
found that BMP-induced SMAD1/5 phosphorylation is
inhibited in breast cancer cells and in CAFs. In addition,
depletion of endogenous Grem1 in CAFs upregulates
BMP/SMAD-dependent ID1/ID3 expression while the
addition of rhGrem1 has the opposite effect. Moreover,
treatment with a selective BMP receptor kinase inhibitor
mimicked the effect of exogenous Grem1 protein by pro-
moting mammosphere formation and fibrogenic marker
expression. However, our results do not exclude the possi-
bility that Grem1 also can act via BMP-independent path-
ways [24]. For example, induction of TGFβ expression by
Grem1 may occur independently of BMP antagonism.
Grem1 was found to promote cell viability, migration, and
invasion in glioma [54] and the invasive phenotype of meso-
thelioma [55] by activating TGFβ/SMAD signaling. More-
over, Grem1 may promote breast tumorigenesis by acting
on signaling pathways distinct from TGFβ family signaling;
in renal tubular cells, Grem1 has been reported to signal via
the vascular endothelial growth factor receptor 2 (VEGFR2)
pathway [21] to promote angiogenesis [56] and to mediate
inflammation and the infiltration of immune-inflammatory
cells [57]. Furthermore, Grem1 may act directly or indir-
ectly by sequestering BMP on endothelial cells and immune
cells and thereby promote tumorigenesis. Irrespective of the
precise mechanisms, our results demonstrate potent pro-
tumorigenic effects of Grem1 on cancer cells and CAFs in
vitro in mono- and in co-culture, as well as a key in vivo
role for Grem1 in stimulating extravasation and for Grem1-
producing CAFs in mediating the intravasation of breast
cancer cells. These two processes, extravasation and intrava-
sation, are the key steps in the dissemination and distant
colonization of primary cancer cells.
(See figure on previous page.)
Fig. 7 GREM1 knockdown attenuates the ability of 19TT breast cancer-associated fibroblasts (CAFs) to promote breast cancer cell intravasation in
a zebrafish co-injection model. a Perivitelline space single injection of MDA-MB-231 cells or co-injection of MDA-MB-231 cells and W21 mesenchymal
stem cells (MSCs), foreskin fibroblasts, or 19TT CAFs, as indicated. The panel shows the representative images. Green, endothelium of zebrafish; red,
mCherry-labeled MDA-MB-231; blue, converted from AmCyan-labeled MSCs or fibroblasts. Yellow arrowheads point to the single intravasated cells in
the head and tail regions of zebrafish. Left, cell migration in the perivitelline space; middle, the image of a zebrafish embryo body. Right, visualization
of the intravasated cells in the posterior of the embryo. The graph shows the quantification of the number of intravasated cells in each embryonic
body at 3 days post-injection (dpi). The results are expressed as the mean ± s.e.m., n = 2. Student’s t test, **P≤ 0.01, ***P≤ 0.001. b Perivitelline space
co-injection of MDA-MB-231 cells and 19TT CAFs with/without GREM1 knockdown. The panel and graph description are the same as described in a.
The results are expressed as the mean ± s.e.m., n = 2. Student’s t test, **P≤ 0.01. c Schematic of the working model of Grem1 function in breast cancer
progression. Grem1 expression in fibroblasts is induced by factors (such as TGFβ from breast cancer cells or maybe other stromal cells (that produce
inflammatory cytokines). Grem1 could activate fibroblasts into CAFs. CAFs might present a desmoplastic microenvironment, thereby promote cancer
cell invasion. Grem1 itself could promote the stemness and invasion of breast cancer cells
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Conclusion
Our results identified Grem1 as a driving force of breast
cancer progression by affecting the behavior of both can-
cer cells and neighboring CAFs. Antibodies that neutralize
Grem1’s function in the Grem1-BMP interaction have
been described, which may be beneficial not only for the
treatment of pulmonary arterial hypertension [58] but also
for breast cancer (by inhibiting breast cancer progression).
In addition, BMP agonists that are engineered to prevent
interactions with Grem1, as has been performed for
Noggin [59], or BMP-mimetic small-molecule drugs
[60, 61], could be beneficial in the treatment of breast
cancer patients with high Grem1 expression.
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Additional file 1: Table S1. Quantitative real-time PCR Primers.
(XLSX 12 kb)
Additional file 2: Figure S1. Related to Fig. 1. a Kaplan-Meier analysis of
metastasis free survival based on GREM1 expression. Endpoint is distant
metastasis free survival (MFS). b-e Kaplan-Meier survival analysis of
different breast cancer molecular subtypes, HER2+ (b), Triple- (c), ER+ (d),
and ER- (e). The subjects were divided into 3 quantiles. Endpoint is
distant MFS. f Scatterplot showing the positive correlation between
GREM1 and stromal genes / desmoplastic markers expression in clinical
datasets.
Pearson’s coefficient tests were performed to assess statistical
significance. (DOCX 766 kb)
Additional file 3: Figure S2. Related to Fig. 2. a GREM1 expression in
W21 MSCs after treatment with conditioned medium (CM) from breast cell
lines (M1, MDA-MB-21, MCF7). Expression was normalized to the parallel time
control of normal medium treatment. The results are expressed as the
mean ± s.d, n = 3. Student’s t test, *P < 0.05, ***P ≤ 0.001. b TGFβ3 (5 ng/ml),
or TNFα (10 ng/ml), or IL1β (10 ng/ml) induces GREM1 expression in W21
mesenchymal stem cells (MSCs). Expression was normalized to the parallel
time control of buffer treatment. The results are expressed as the mean ± s.d.,
n = 3. Student’s t test, *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. (DOCX 296 kb)
Additional file 4: Figure S3. Related to Fig. 3. a, b qRT-PCR measurement
for BMPs and BMP receptors in M1, MDA-MB-231 and MCF7 cell lines. ΔCt
values are labeled to show expression abundance. c rhGrem1 upregulates
stem cell transcription factors in M1 cells. GAPDH was used as an internal
control. The results are expressed as the mean ± s.d., n = 3. Student’s t test,
*P < 0.05, **P ≤ 0.01. (DOCX 368 kb)
Additional file 5: Figure S4. Related to Fig. 4. a GREM1 OE upregulates
the expression of EMT transcription factors and markers in M1 cells.
GAPDH was used as an internal control. The results are expressed as the
mean ± s.d., n = 3. Student’s t test, *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. b
exogenous administration of rhGrem1 inhibits BMP-induced SMAD1/5/8
phosphorylation (pSMAD1/5/8) in MDA-MB-231 and M2 cell lines.
(DOCX 175 kb)
Additional file 6: Figure S5. Related to Fig. 5. GREM1 overexpression
(OE) in fetal mesenchymal stem cells (MSCs) W21 shows fibroblast-like
characteristics. a Stable GREM1 OE in MSCs W21 inhibits BMP6 (5 ng/ml)
induced SMAD1/5/8 phosphorylation (pSMAD1/5/8). Left, relative mRNA level
determined by qRT-PCR. GAPDH was used as internal control. The results are
expressed as the mean ± s.d., n = 3. Student’s t test, ***P ≤ 0.001. b qRT-PCR
analysis of selected BMP targets, TGFβb pathway constituents/targets,
fibroblast activation markers, matrix metalloproteinases, in W21 MSCs with/
without GREM1 stable OE. GAPDH was used as internal control. The results are
expressed as the mean ± s.d., n = 3. Student’s t test, *P < 0.05, **P ≤ 0.01,
***P ≤ 0.001. c Western blot to detect indicated proteins level change after
GREM1 OE in W21 MSCs. d W21 MSCs with/without GREM1 OE were stained
with fluorescein-phalloidin (green) to visualize F-actin. DAPI was used for
nuclear staining (blue). e Collagen gel contraction assay. W21 MSCs with/
without GREM1 OE were embedded in collagen gels. After 24, 48, and 72 h,
the area of each gel (white dash circle) was imaged and quantified. Left,
representative images of contracted gels. Right, percentage of gel
contraction gel. Quantification is shown in Methods. The results are
expressed as the
mean ± s.d., n = 3. Student’s t test, *P < 0.05, **P ≤ 0.01. f qRT-PCR analysis of
selected genes in W21 MSCs after 48 hours treatment with recombinant
human Grem1 (rhGrem1) protein (500 ng/ml) or BMP type I receptors
inhibitor LDN193198 (120 nM). GAPDH was used as internal control. The
results are expressed as the mean ± s.d., n = 3. Student’s t test, *P < 0.05, **P
≤ 0.01,
***P ≤ 0.001. (DOCX 447 kb)
Additional file 7: Figure S6. Related to Fig. 6. Spheroid invasion assays.
a Schematic illustration of spheroid production. Briefly, mCherry-labeled
MDA-MB-231 or MCF7 cells (Red) were mixed with AmCyan (converted
to blue)-labeled 19TT breast cancer-associated fibroblasts (CAFs) at a ratio
of 1:1. Mixtures were cultured for 7 days in hanging drops to obtain
spheroids. b 19TT CAFs promotes MCF7 cells invasion. Left, representative
images of spheroids at days 0, 2, and 4. Red, MCF7 cells; Blue, 19TT CAFs.
Right, the relative invasion area was quantified as area difference at days
2 and 4,
relative to day 0. The results are expressed as the as the mean ± s.d., n =
8. Student’s t test, **P ≤ 0.01. (DOCX 197 kb)
Additional file 8: Figure S7. Related to Fig. 7. GREM1 overexpression
(OE) in W21 mesenchymal stem cells (MSCs) promotes breast cancer cells
intravasation in zebrafish embryo perivitelline space coinjection model.
Perivitelline space co-injection of MDA-MB-231 cells and W21 MSCs with/
without GREM1 stable OE. The panels show representative images. Green,
endothelium of zebrafish; Red, mCherry-labelled MDA-MB-231; Blue,
converted from AmCyan-labelled W21. Yellow arrowheads point to single
intravasated cells in the head and tail regions of zebrafish. Left, cells
migration in the perivitelline space; middle, image of zebrafish embryo
body; Right, visualization of intravasated cells in the posterior of embryo.
The graph shows quantification of the number of intravasated cells in
each embryonic body at 3 days post injection (dpi). The results are
expressed as the
mean ± s.e.m., n=2. Student’s t test, **P ≤ 0.01. (DOCX 269 kb)
Additional file 9: Figure S8. Related to Fig. 1. a GREM1 mRNA
expression in epithelium and stroma compartments in breast cancer
dataset GSE14548. Epithelium and stroma were extracted from normal
breast, grade I, II, III ductal carcinoma in situ (DCIS) and invasive breast
cancer tissue using laser capture. b GREM1 expression in epithelial cells,
leukocytes, fibroblasts and endothelial cells in colorectal cancer dataset
GSE39396. The each specific type of cells were isolated by flow
cytometry. (DOCX 177 kb)
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